Gynecomastia on Testosterone Cypionate: Incidence, Severity, and Realistic Expectations

What the Depo-Testosterone label says

Depo-Testosterone, the intramuscular testosterone cypionate product, states that gynecomastia may develop and occasionally persists in patients being treated for hypogonadism. Its adverse reactions list, introduced as reactions that have occurred with some androgens, names gynecomastia first under endocrine and urogenital reactions, alongside excessive frequency and duration of penile erections and oligospermia at high doses [1]. The list gives no frequency [1]. Carcinoma of the breast in men is a contraindication to the product [1].

Why testosterone cypionate can enlarge breast tissue

Aromatase converts androgens to estrogens [2]. Estrogens stimulate breast tissue growth and androgens inhibit it, and most gynecomastia results from deficient androgen action or excessive estrogen action in the breast [3].

How common is it?

The label gives no rate [1]. In men generally, the 2019 guideline puts gynecomastia prevalence at 32 to 65 percent, depending on age and the criteria used [4]. That is not a rate for men on testosterone cypionate.

Symptoms, and telling it apart from breast cancer

Gynecomastia can cause local pain and tenderness, and most cases are benign and cosmetic rather than clinically important [3]. Breast cancer in men is much less common than benign gynecomastia, and careful physical examination usually separates the two [3]. The guideline's assessment includes examination of the breast and genitalia with testicular ultrasound, laboratory tests, breast imaging when the examination is equivocal, and core needle biopsy for suspicious lesions [4].

What the guideline says about treatment

The 2019 guideline states that SERMs, aromatase inhibitors and non-aromatizable androgens are not justified in general, recommends watchful waiting once the underlying condition is treated or the responsible substance is discontinued, and calls surgery the treatment of choice for long-lasting gynecomastia [4]. It also says testosterone treatment should be offered to men with proven testosterone deficiency [4].

Tamoxifen data come mainly from idiopathic gynecomastia rather than testosterone-related cases. In a preliminary report, 61 Chinese men with idiopathic gynecomastia took tamoxifen 40 mg daily for one to four months (median two months); 80 percent had complete regression of breast swelling, with no comparison group, and no long-term side effects were observed over a median 36 months [5].